GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Impax Laboratories, Inc. (IPXL) [hlAlert]

Rating:
Buy IPXL
up 246.49 %

Impax Laboratories, Inc. (IPXL) rated Buy with price target $26 by Collins Stewart

Posted on: Tuesday,  Mar 15, 2011  8:25 AM ET by Collins Stewart

Collins Stewart rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on 03/15/2011. Previously Collins Stewart rated Buy Impax Laboratories, Inc. (NASDAQ: IPXL) on
12/15/2009., when the stock price was $12.69. Since then, Impax Laboratories, Inc. has gained 246.49% as of 01/20/2016's recent price of $43.97.
If you would have followed the previous Collins Stewart's recommendation on IPXL, you would have gained 246.49% of your investment in 2227 days.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Collins Stewart's research department is built around a number of sector-specialist teams. Our analysts are leaders in their area of specialisation and combine deep industry knowledge with decades of stock broking experience to produce insightful, independent sector research. Our research approach encompasses Questâ„¢ principles and focuses on cash-driven valuation techniques. Research is a Collins Stewart cornerstone; it is leveraged throughout the organisation.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/15/2011 8:25 AM Buy
None
24.75 26.00
as of 12/30/2011
1 Week down  -0.24 %
1 Month up  0.14 %
3 Months up  12.61 %
1 YTD up  0.29 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/15/2009 8:25 AM Buy
None
12.69 16.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy